Novel Biomarkers for Lupus Nephritis in the “OMICS” Era

Title:Novel Biomarkers for Lupus Nephritis in the “OMICS” Era

Volume: 28 Issue: 29

Author(s): Raphael Dias, Ursula Gramiscelli Hasparyk, Monisi Peres Lopes, João Luiz Vieira Monteiro de Barros and Ana Cristina Simões e Silva*

Affiliation:

• Interdisciplinary Laboratory of Medical Investigation, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG,Brazil

Keywords: Biomarkers, lupus nephritis, monitoring, diagnosis, therapeutic targets, genomics, transcriptomics, proteomics, metabolomics.

Abstract: Lupus nephritis (LN) is severe renal comorbidity associated with systemic lupus erythematosus (SLE), a complex autoimmune disorder with high morbidity and mortality. Diagnosis and monitoring of LN patients still rely on renal biopsy, a procedure that exposes patients to a variety of risks and is not capable of providing longitudinally information about disease prognosis. In this review, we summarized current data of recent promising biomarkers developed in the precision medicine era, particularly under genomic, transcriptomic, proteomic, and metabolomic techniques. Genome-wide association studies have been evaluating the role of endogenous elements beyond the autoimmunity in LN. Transcriptomic methods, including single-cell sequencing, are potential tools in identifying inflammatory signatures, miRNAs, and gene expression. Proteomic measures, including anti-C1q antibodies, cytokines, TLRs, VCAM-1, NGAL osteopontin, angiostatin, have been considered helpful to provide a more profound comprehension of the disease pathogenic processes. Metabolomic approaches may identify several abnormal metabolite profiles related to the impairment of cellular functions. Together, these accurate, non-invasive, and moderate-cost propedeutic resources may be the novel tools for recognizing, distinguishing, and predicting LN progression and prognosis. Furthermore, omics evaluation may also predict responsiveness to treatment and, consequently, change the way we manage LN cases in the near future.

Cite this article as:

Dias Raphael , Hasparyk Gramiscelli Ursula , Lopes Peres Monisi , de Barros Luiz Vieira Monteiro João and Simões e Silva Cristina Ana *, Novel Biomarkers for Lupus Nephritis in the “OMICS” Era, Current Medicinal Chemistry 2021; 28 (29) . https://dx.doi.org/10.2174/0929867328666210212102438